A minimally invasive system for glucose area under the curve measurement using interstitial fluid extraction technology: Evaluation of the accuracy and usefulness with oral glucose tolerance tests in subjects with and without diabetes

Diabetes Technology and Therapeutics

Volumn 14, Issue 6, 2012, Pages 485-491

  Sakaguchi, Kazuhiko ^a   Hirota, Yushi ^a   Hashimoto, Naoko ^a   Ogawa, Wataru ^a   Sato, Toshiyuki ^b   Okada, Seiki ^b   Hagino, Kei ^b   Asakura, Yoshihiro ^b   Kikkawa, Yasuo ^b   Kojima, Junko ^b   Maekawa, Yasunori ^b   Nakajima, Hiromu ^c  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SYSMEX CORPORATION   (Japan)

^c OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; SODIUM ION;

ACCURACY; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD GLUCOSE MONITORING; CALCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; EXTRACTION; FOREARM; GLUCOSE BLOOD LEVEL; HUMAN; HYDROGEL; HYDROGEL PATCH; IMPAIRED GLUCOSE TOLERANCE; INTERMETHOD COMPARISON; INTERSTITIAL FLUID; INTERSTITIAL FLUID GLUCOSE; MEAL; MINIMALLY INVASIVE PROCEDURE; NEEDLE; ORAL GLUCOSE TOLERANCE TEST; PAIN; PLASTIC MICRONEEDLE ARRAY; POSTPRANDIAL STATE; PRIORITY JOURNAL; REFERENCE VALUE; SELF MONITORING; TECHNOLOGY;

AREA UNDER CURVE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; EXTRACELLULAR FLUID; FASTING; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERGLYCEMIA; INSULIN; MALE; MONITORING, PHYSIOLOGIC; POSTPRANDIAL PERIOD; QUESTIONNAIRES;

EID: 84861981234     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2011.0255     Document Type: Article

References (24)

1. DECODE Study Group: Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003;26:688-696.
2. Nakagami T; DECODA Study Group: Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin: the DECODA study. Diabetologia 2004;47:385-394.
3. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 2002;359:2072-2077. (Pubitemid 34680970)
4. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M: Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004;25:10-16. (Pubitemid 38055587)
5. International Diabetes Federation: Guideline for Management of Postmeal Glucose. Brussels: International Diabetes Federation, 2007.
6. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, Ziegelasch HJ, Lindner J: Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39:1577-1583. (Pubitemid 26397370)
7. American Diabetes Association: Standards of medical care in diabetes - 2011. Diabetes Care 2011;34(Suppl 1):S11-S61.
8. Esposito K, Ciotola M, Carleo D, Schisano B, Sardelli L, Di Tommaso D, Misso L, Saccomanno F, Ceriello A, Giugliano D: Postmeal glucose peaks at home associate with carotid initima-media thickness in type 2 diabetes. J Clin Endocrinol Metab 2008;93:1345-1350. (Pubitemid 351519731)
9. Monnier L, Colette C, Owens DR: Integrating glycaemic variability in the glycaemic disorders of type 2 diabetes: a move towards a unified glucose tetrad concept. Diabetes Metab Res Rev 2009;25:393-402.
10. Kilpatrick ES: Arguments for and against the role of glucose variability in the development of diabetes complications. J Diabetes Sci Technol 2009;3:649-655.
11. Edelman SV, Bailey TS: Continuous glucose monitoring health outcomes. Diabetes Technol Ther 2009;11(Suppl 10):S68-S74.
12. Sato T, Okada S, Hagino K, Asakura Y, Kikkawa Y, Kojima J, Maekawa Y, Nakajima H, Asano K: A novel technique of glucose area under the curve monitoring with interstitial fluid. Diabetes Technol Ther 2011;12:1194-1200.
13. Bina DM, Anderson RL, Johnson ML, Bergenstal RM, Kendall DM: Clinical impact of prandial state, exercise, and site preparation of the equivalence of alternative-site blood glucose testing. Diabetes Care 2003;26:981-985. (Pubitemid 36929235)
14. Ellison JM, Stegmann JM, Colner SL, Michael RH, Sharma MK, Ervin KR, Horwitz DL: Rapid changes in postprandial blood glucose produce concentration differences at finger, forearm, and thigh sampling site. Diabetes Care 2002;25:961-964. (Pubitemid 41110478)
15. Koschinsky T, Jungheim K, Heinemann L: Glucose sensors and the alternate site testing-like phenomenon: relationship between rapid blood glucose changes and glucose sensor signals. Diabetes Technol Ther 2003;5:829-841.
16. Kulcu E, Tamada JA, Reach G, Potts RO, Lesho MJ: Physiological differences between interstitial glucose and blood glucose measured in human subjects. Diabetes Care 2003;26:2405-2409. (Pubitemid 36993334)
17. Standards Australia. Australian Standard® Glycemic Index of Food. Sydney: Standards Australia, 2007.
18. Brouns F, Bjorck I, Frayn KN, Gibbs AL, Lang V, Slama G, Wolever TM: Glycaemic index methodology. Nutr Res Rev 2005;18:145-171. (Pubitemid 40826920)
19. Rosenstock J, Hassman DR, Madder RD, Brazinsky SA, Farrell J, Khutoryansky N, Hale PM; Repaglinide Versus Nateglinide Comparison Study Group: Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 2004;27:1265-1270. (Pubitemid 38679968)
20. Shimabukuro M, Higa N, Chinen I, Yamakawa K, Takasu N: Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study. J Clin Endocrinol Metab 2006;91:837-842. (Pubitemid 43357747)
21. Pattzi HM, Pitale S, Alpizar M, Bennett C, O'Farrell AM, Li J, Cherrington JM, Guler HP; PHX1149-PROT202 Study Group: Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial. Diabetes Obes Metab 2010;12:348-355.
22. Hussey EK, Clark RV, Amin DM, Kipnes MS, O'Connor-Semmes RL, O'Driscoll EC, Leong J, Murray SC, Dobbins RL, Layko D, Nunez DJ: Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus. J Clin Pharmacol 2010;56:623-635.
23. Olson DE, Rhee MK, Herrick K, Ziemer DC, Twombly JG, Phillips LS: Screening for diabetes and pre-diabetes with proposed A1C-based diagnostic criteria. Diabetes Care 2010;33:2184-2189.
24. Mostafa SA, Davies MJ, Srinivasan BT, Carey ME, Webb D, Khunti K: Should glycated haemoglobin (HbA1c) be used to detect people with type 2 diabetes mellitus and impaired glucose regulation? Postgrad Med J 2010;86:656-662.